.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

OPTISON Drug Profile

« Back to Dashboard
Optison is a drug marketed by Ge Healthcare and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

This drug has thirty-nine patent family members in twenty-seven countries.

The generic ingredient in OPTISON is albumin human. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the albumin human profile page.

Summary for Tradename: OPTISON

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1

Pharmacology for Tradename: OPTISON

Clinical Trials for: OPTISON

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 1997RXYes6,723,303<disabled>Y <disabled>
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 1997RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: OPTISON

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 19975,529,766<disabled>
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 19975,573,751<disabled>
Ge Healthcare
OPTISON
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 19975,558,094<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: OPTISON

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,875,420 Method of ultrasound imaging<disabled in preview>
5,666,526 Method and system for supporting scrollable, updatable database queries<disabled in preview>
6,156,292 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OPTISON

Country Document Number Estimated Expiration
Hungary218018<disabled in preview>
Norway313577<disabled in preview>
Canada2273140<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OPTISON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00673Netherlands<disabled>PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
2014 00034Denmark<disabled>PRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: C(2013)9835 20131220
C0050France<disabled>PRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/428/001 DU 20080111; REGISTRATION NO/DATE AT EEC: EU/1/07/428/001 DU 20080111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc